Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 15/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566564 | 0.94 | ADORA2A (0.52) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5566168 | 0.93 | ADORA2A (0.53) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5568854 | 0.91 | ADORA2A (0.53) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5560913 | 0.89 | ADORA2A (0.55) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5567820 | 0.89 | ADORA2A (0.55) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5561320 | 0.89 | ADORA2A (0.53) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5566362 | 0.89 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5560662 | 0.88 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5561503 | 0.88 | ADORA2A (0.57) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5560362 | 0.88 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371748-B2 | Benzothiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1636223-B1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| EP-1448198-B1 | NICOTIN-OR ISONICOTIN BENZOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-10-31 | — | — | EP | disclosed |
| EP-1636223-A1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. Hoffman-la Roche AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005000842-A1 | BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMAN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040235915-A1 | Benzothiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | US | disclosed |
| EP-1448198-A1 | NICOTIN-OR ISONICOTIN BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-25 | — | — | EP | disclosed |
| US-6620811-B2 | Adenosine receptor antagonists; nervous system and cardiovascular disorders; Parkinson*s, Huntington*s, and Alzheimer* disease; antiasthmatics, antiallergens | HOFFMANN-LA ROCHE INC. | 2003-09-16 | — | — | US | disclosed |
| US-20030134854-A1 | Isonicotin- and nicotinamide derivatives of benzothiazoles | F.HOFFMANN-LA ROCHE AG (CH) | 2003-07-17 | — | — | US | disclosed |
| WO-2003043636-A1 | NICOTIN-OR ISONICOTIN BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235915-A1 | Benzothiazole derivatives | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885ADORA2B 4/4885 |
| US-20030134854-A1 | Isonicotin- and nicotinamide derivatives of benzothiazoles | ADORA1, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 1/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.